Search clinical trials for: Dolutegravir/lamivudine/abacavir

Total 741 results

Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals (AVERTAS-1)

Cardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV Cardiomyopathy

Denmark
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

HIV Infections

United States, South Africa, Thailand, Botswana
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Australia, New Zealand
University College Dublin
ViiV Healthcare; Mater Misericordiae University Hospital

Unknown

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (TAISTR)

Human Immunodeficiency Virus

Ireland
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

HIV

United Kingdom
Centre Hospitalier Régional d'Orléans

Terminated

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients (MONCAY)

HIV

France
Neuroscience Trials Australia
Macquarie University, Australia; Calvary Health Care Bethlehem; Westmead Hosptial and other collaborators

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (Lighthouse)

Amyotrophic Lateral Sclerosis

Australia
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (TRIUMPH)

HIV Infections

Germany
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
ViiV Healthcare

Completed

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Puerto Rico, Costa Rica, Panama
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
Fundación Huésped
ViiV Healthcare

Completed

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study (PADDLE)

HIV-1 Infection

Argentina
Fundacion Clinic per a la Recerca Biomédica

Unknown

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

HIV-1-infection | Solid Organ Transplant

Spain
Glaxo Wellcome

Unknown

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

HIV Infections

United States
University of Edinburgh
Medical Research Council; NHS Lothian

Recruiting

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome (AGS-RTI)

Aicardi-Goutières Syndrome

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
Shanghai Public Health Clinical Center

Not yet recruiting

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

Acquired Immunodeficiency Syndrome
GlaxoSmithKline

Completed

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Blood Levels of Abacavir in HIV Infected Adolescents

HIV Infections

United States, Puerto Rico
GlaxoSmithKline

Completed

Pharmacokinetic Study Of EPZICOM Tablet

HIV Infection

Japan
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
Glaxo Wellcome

Completed

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

HIV Infections

United States
Glaxo Wellcome

Completed

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

HIV Infections | Lipodystrophy

United States
Novartis Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease

United States
Therapeutic Concepts

Completed

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy (EPZSwitch)

HiV1- Positive

United States
Rijnstate Hospital
GlaxoSmithKline

Completed

FREE Study: Efficacy and Toxicity of Trizivir

HIV Infections

Netherlands
GlaxoSmithKline

Completed

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV (HEAT)

HIV Infection

United States, Puerto Rico
ViiV Healthcare

Completed

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

HIV Infection

United States
Pfizer
ViiV Healthcare

Completed

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

Healthy Volunteers

United States
Erasmus Medical Center
Catharina Ziekenhuis Eindhoven; Maasstad Hospital, Rotterdam; MC Haaglanden,... and other collaborators

Recruiting

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study (DUALING)

Hiv

Netherlands
University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Terminated

Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

HIV Infections

Kenya
Societa' Italiana Di Malattie Infettive E Tropicali

Recruiting

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) (EDOLAS)

HIV-1-infection

Italy
Duke University
GlaxoSmithKline; Kilimanjaro Christian Medical Centre, Tanzania; Kibongoto National...

Completed

Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST) (THIRST)

HIV | Tuberculosis

Tanzania
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
Saint Michael's Medical Center
ViiV Healthcare

Active, not recruiting

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) (Sound)

Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

HIV-1 Infection

France
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
University of Liege

Active, not recruiting

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs (IDOLTIB)

HIV Infections

Belgium
St. Luke's-Roosevelt Hospital Center
Gilead Sciences

Completed

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects (TRU)

HIV

United States
Glaxo Wellcome

Completed

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

HIV Infections

United States

3

Subscribe